SCHEMBL4070774

SCHEMBL4070774

CCC(=O)N(Cc1ccc2c(c1)OCO2)Cc1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.52
ALDH1A1 P00352 9/20 0.52
KDM4E B2RXH2 4/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 2/20 0.49
MAPK1 P28482 3/20 0.48
USP2 O75604 3/20 0.48
HPGD P15428 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
TSHR P16473 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074176 0.87 ALDH1A1 (0.50) PKMALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4069193 0.76 KDM4E (0.75) PKMALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL8081828 0.71 SLC6A2 (0.58) ALDH1A1
SCHEMBL29432986 0.69 KDM4E (0.71) KDM4EMEN1KMT2APOLB
SCHEMBL30345286 0.68 SRD5A2 (0.54) PKMALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL20363079 0.68 TRPM8 (0.63) ALDH1A1HSD17B10SMN1; SMN2MAPTMAPK1
SCHEMBL5136731 0.67 TSHR (0.59) PKMALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL16598448 0.67 KDM4E (0.66) ALDH1A1KDM4EHSD17B10SMN1; SMN2MAPT
SCHEMBL18321322 0.67 POLB (0.47) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL3641107 0.67 LMNA (0.50) KDM4EHSD17B10SMN1; SMN2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG PKM 2595/4885ALDH1A1 1055/4885KDM4E 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.